ClinicalTrials.gg
WithdrawnNCT02625077VANTAGEUpdated Mar 27, 2017

Valvuloplasty as Alternative to Toupet Fundoplication for GERD

An interventional study of Laparoscopic gastroesophageal valvuloplasty and Laparoscopic Toupet fundoplication in Gastroesophageal Reflux and Hernia, Hiatal, sponsored by Meander Medical Center. Withdrawn at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-27.

Sponsored by Meander Medical Center · Not applicable, Interventional, and Treatment

Why this study was withdrawn
Ethical concerns with efficacy of technique.
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This monocenter randomized controlled trial aims to compare postoperative outcomes of a laparoscopic valvuloplasty with a Toupet fundoplication in patients with GERD with a maximum hiatal hernia of 3cm. In addition, an economic evaluation of the new intervention will be done in order to determine cost-effectiveness and costs per quality-adjusted life-year (QALY).

Read the detailed description

This is a prospective, interventional, double-blinded, monocenter randomized controlled trial comparing a laparoscopic gastroesophageal valvuloplasty to laparoscopic Toupet fundoplication in patients with proven GERD with a maximum hiatal hernia of 3cm. In this design, both patient and researcher are blinded to the treatment allocation.

Block randomization will be used to ensure an equal number in each treatment arm. Block randomization works by randomizing participants within blocks such that an equal number are assigned to each treatment. To reduce selection bias by predictability of the treatment allocation, random block sizes are used. Also the investigator is kept blind to the size of each block. A computer is used to generate 15 blocks for each participating center with random block sizes of 4, 8 and 12. Allocation proceeds by randomly selecting one of the orderings and assigning the next block of participants to study groups according to the specified sequence.

Patients will be included during a two-year period and followed for a minimum of one year. When a patient is referred to a participating surgeon for antireflux surgery, he or she will receive study information to give them sufficient time for consideration. The surgeon will ensure all required pre-operative diagnostic tests are performed and that the indication for surgery is valid. During a follow-up visit, the surgeon ascertains that the patient complies with all inclusion criteria and does not meet any of the exclusion criteria. Study participation will be discussed and after informed consent is obtained, the patient will be included in the trial.

After inclusion, the patient is immediately randomized but treatment allocation is not yet shared with the surgeon. The patient will receive validated questionnaires to record the pattern of symptoms, quality of life, medication and medical care usage. Data from the pre-operative tests will be recorded.

On the day of surgery, the surgeon will be able to see treatment allocation and after performing the appropriate surgical procedure, records the course and specifics of the surgical procedure. Patients will receive a diary to record their meals and symptoms.

Follow-up in the outpatient clinic will take place at the surgeon's discretion. At fixed moments: 3, 6 and 12 months after surgery, the patients will once more receive validated questionnaires. Also at about three months, a follow-up manometry and 24-hour pH and/or impedance monitoring will be performed.

A power analysis was performed to calculate the sample size. Our primary aim was to compare the effect of both surgical procedures. Based upon the current medical literature, the objective/subjective success rate for the laparoscopic Toupet fundoplication is around 88%. Pilot data from a retrospective cohort of patients that underwent valvuloplasty report a subjective success rate of 96%. Our hypothesis was that the gastroesophageal valvuloplasty is not inferior to the Toupet fundoplication when comparing its effects on acid control.

To prove non-inferiority of the valvuloplasty regarding acid reflux control, using a non-inferiority limit of 5%, 73 patients are required in each group. In all power calculations, a significance of 5% and power of 90% was used.

To accommodate for a loss to follow-up of up to 10 percent, a total sample size of 160 was chosen.

02

Conditions studied

  • Gastroesophageal Reflux
  • Hernia, Hiatal

Keywords

  • Valvuloplasty
  • Fundoplication
  • Acid reflux
  • GERD
  • Reflux disease
  • Hiatal hernia
03

In context

Gastroesophageal Reflux

1,086 studies on the registry are indexed under Gastroesophageal Reflux; 187 are open to participants now.

Browse Gastroesophageal Reflux studies →

Lead sponsor

Meander Medical Center is the lead sponsor of 12 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Objectively proven GERD (by gastroscopy and/or 24-hour pH and/or impedance monitoring)
  • Age ≥18
  • Written informed consent for study participation

Exclusion criteria

Exclusion Criteria:

  • BMI ≥ 30
  • Hiatal hernia >3cm
  • Achalasia
  • Previous gastric surgery
  • Previous esophageal surgery
  • Inability to understand the Dutch language
  • Inability to understand and/or fill in the questionnaires
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Laparoscopic valvuloplasty

    Via laparoscopy, using three sutures a part of the esophagus is folded (similar to the way parts of a telescope slide in each other) into the stomach, creating a valve on the inside to prevent gastric acid to enter the esophagus.

    Procedure: Laparoscopic gastroesophageal valvuloplasty

  • Active comparator
    Laparoscopic Toupet fundoplication

    Via laparoscopy, the entire stomach is mobilized and folded around itself posteriorly, creating a partial (270 degrees) fundoplication.

    Procedure: Laparoscopic Toupet fundoplication

Interventions

  • ProcedureLaparoscopic gastroesophageal valvuloplasty
  • ProcedureLaparoscopic Toupet fundoplication
06

What researchers measure

Primary outcomes

  1. Success rate, objective

    Defined as % of patients with normal values of reflux measured by pH and impedance monitoring

    Time frame: 3 months post-operative

Secondary outcomes

  1. Success rate, subjective

    Defined as % of patients with Visick score I or II

    Time frame: 3 months post-operative, 1 year post-operative

  2. Percent of patients with complaints of functional dysphagia according to the Rome III criteria

    % of patients with complaints of functional dysphagia according to the Rome III criteria.

    Time frame: 3 months post-operative, 1 year post-operative

  3. Cost-effectiveness

    Cost-effectiveness will be calculated by comparing the direct and indirect medical cost related to both strategies up until one years after the operation.

    Time frame: 1 year post-operative

  4. Mortality rate

    Defined as in-hospital mortality or out of hospital mortality within 30 days

    Time frame: 30 days

  5. Complication rate

    Intra-operative complication rate

    Time frame: During surgery

  6. Conversion rate

    Time frame: During surgery

  7. Disease related reoperation rate

    % of patients requiring redo surgery for persisting complaints or recurrence

    Time frame: 1 year

07

Study locations

1 site
  • Meander Medical Center
    Amersfoort, Utrecht 3813 TZ, Netherlands
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02625077
Lead sponsor
Meander Medical Center
Responsible party
R.C. Tolboom, MD (Project Leader, Meander Medical Center) — Principal investigator
First posted
Dec 9, 2015
Start date
Jan 2016
Primary completion
Jan 2019 (estimated)
Completion
Jan 2019 (estimated)
Last update
Mar 27, 2017

Study contacts

Werner A Draaisma, MD, PhD
study director · Meander Medical Center
Ivo AM Broeders, MD, PhD
principal investigator · Meander Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion